Clinical features and outcomes of uterine and ovarian carcinosarcoma

Amy L. Jonson, Robin L. Bliss, Alexander Truskinovsky, Patricia Judson, Peter A Argenta, Linda F Carson, Kathryn E Dusenbery, Levi S Downs

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. The objective of this study was to compare the clinical presentation and outcomes of women with ovarian and uterine carcinosarcoma (CS). Methods. We performed a retrospective review of patients treated for uterine or ovarian CS from 1952 to 2003. Fisher's Exact Test was used to compare patient characteristics. Survival curves were estimated using the Kaplan-Meier method and compared using the log rank test. Results. We identified 87 patients with uterine CS and 18 with ovarian CS. There was no difference in age, body mass index, parity, menopausal status, family history of cancer, history of pelvic radiation, diabetes or hypertension between the two groups. 43% of women with uterine CS presented at stage I/II, compared to 28% of women with ovarian tumors (P = 0.0003). 82% of patients with ovarian tumors received adjuvant chemotherapy with or without radiation; 51% of the patients in the uterine CS group received adjuvant radiation therapy. The median length of follow-up was 13 months. There was no difference in the Kaplan-Meier estimates of overall survival between the two disease sites. The median survival for uterine CS patients was 16 months, compared to 11 months in the ovarian CS group; HR = 0.991 (95% CI = 0.534, 1.839). Conclusions. We found no differences in patient demographics between the two groups. Despite differences in stage and initial treatment, there was no difference in survival between women with uterine and ovarian CS.

Original languageEnglish (US)
Pages (from-to)561-564
Number of pages4
JournalGynecologic Oncology
Volume100
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Carcinosarcoma
Survival
Pelvic Neoplasms
Radiation
Kaplan-Meier Estimate
Adjuvant Chemotherapy
Parity
Neoplasms
Body Mass Index
Radiotherapy
Demography
Hypertension

Keywords

  • Carcinosarcoma
  • Cervix
  • Ovary

Cite this

Jonson, A. L., Bliss, R. L., Truskinovsky, A., Judson, P., Argenta, P. A., Carson, L. F., ... Downs, L. S. (2006). Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecologic Oncology, 100(3), 561-564. https://doi.org/10.1016/j.ygyno.2005.09.017

Clinical features and outcomes of uterine and ovarian carcinosarcoma. / Jonson, Amy L.; Bliss, Robin L.; Truskinovsky, Alexander; Judson, Patricia; Argenta, Peter A; Carson, Linda F; Dusenbery, Kathryn E; Downs, Levi S.

In: Gynecologic Oncology, Vol. 100, No. 3, 03.2006, p. 561-564.

Research output: Contribution to journalArticle

Jonson, AL, Bliss, RL, Truskinovsky, A, Judson, P, Argenta, PA, Carson, LF, Dusenbery, KE & Downs, LS 2006, 'Clinical features and outcomes of uterine and ovarian carcinosarcoma', Gynecologic Oncology, vol. 100, no. 3, pp. 561-564. https://doi.org/10.1016/j.ygyno.2005.09.017
Jonson, Amy L. ; Bliss, Robin L. ; Truskinovsky, Alexander ; Judson, Patricia ; Argenta, Peter A ; Carson, Linda F ; Dusenbery, Kathryn E ; Downs, Levi S. / Clinical features and outcomes of uterine and ovarian carcinosarcoma. In: Gynecologic Oncology. 2006 ; Vol. 100, No. 3. pp. 561-564.
@article{0d752bdfdff64c0ebbde51f25e0b68b0,
title = "Clinical features and outcomes of uterine and ovarian carcinosarcoma",
abstract = "Background. The objective of this study was to compare the clinical presentation and outcomes of women with ovarian and uterine carcinosarcoma (CS). Methods. We performed a retrospective review of patients treated for uterine or ovarian CS from 1952 to 2003. Fisher's Exact Test was used to compare patient characteristics. Survival curves were estimated using the Kaplan-Meier method and compared using the log rank test. Results. We identified 87 patients with uterine CS and 18 with ovarian CS. There was no difference in age, body mass index, parity, menopausal status, family history of cancer, history of pelvic radiation, diabetes or hypertension between the two groups. 43{\%} of women with uterine CS presented at stage I/II, compared to 28{\%} of women with ovarian tumors (P = 0.0003). 82{\%} of patients with ovarian tumors received adjuvant chemotherapy with or without radiation; 51{\%} of the patients in the uterine CS group received adjuvant radiation therapy. The median length of follow-up was 13 months. There was no difference in the Kaplan-Meier estimates of overall survival between the two disease sites. The median survival for uterine CS patients was 16 months, compared to 11 months in the ovarian CS group; HR = 0.991 (95{\%} CI = 0.534, 1.839). Conclusions. We found no differences in patient demographics between the two groups. Despite differences in stage and initial treatment, there was no difference in survival between women with uterine and ovarian CS.",
keywords = "Carcinosarcoma, Cervix, Ovary",
author = "Jonson, {Amy L.} and Bliss, {Robin L.} and Alexander Truskinovsky and Patricia Judson and Argenta, {Peter A} and Carson, {Linda F} and Dusenbery, {Kathryn E} and Downs, {Levi S}",
year = "2006",
month = "3",
doi = "10.1016/j.ygyno.2005.09.017",
language = "English (US)",
volume = "100",
pages = "561--564",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical features and outcomes of uterine and ovarian carcinosarcoma

AU - Jonson, Amy L.

AU - Bliss, Robin L.

AU - Truskinovsky, Alexander

AU - Judson, Patricia

AU - Argenta, Peter A

AU - Carson, Linda F

AU - Dusenbery, Kathryn E

AU - Downs, Levi S

PY - 2006/3

Y1 - 2006/3

N2 - Background. The objective of this study was to compare the clinical presentation and outcomes of women with ovarian and uterine carcinosarcoma (CS). Methods. We performed a retrospective review of patients treated for uterine or ovarian CS from 1952 to 2003. Fisher's Exact Test was used to compare patient characteristics. Survival curves were estimated using the Kaplan-Meier method and compared using the log rank test. Results. We identified 87 patients with uterine CS and 18 with ovarian CS. There was no difference in age, body mass index, parity, menopausal status, family history of cancer, history of pelvic radiation, diabetes or hypertension between the two groups. 43% of women with uterine CS presented at stage I/II, compared to 28% of women with ovarian tumors (P = 0.0003). 82% of patients with ovarian tumors received adjuvant chemotherapy with or without radiation; 51% of the patients in the uterine CS group received adjuvant radiation therapy. The median length of follow-up was 13 months. There was no difference in the Kaplan-Meier estimates of overall survival between the two disease sites. The median survival for uterine CS patients was 16 months, compared to 11 months in the ovarian CS group; HR = 0.991 (95% CI = 0.534, 1.839). Conclusions. We found no differences in patient demographics between the two groups. Despite differences in stage and initial treatment, there was no difference in survival between women with uterine and ovarian CS.

AB - Background. The objective of this study was to compare the clinical presentation and outcomes of women with ovarian and uterine carcinosarcoma (CS). Methods. We performed a retrospective review of patients treated for uterine or ovarian CS from 1952 to 2003. Fisher's Exact Test was used to compare patient characteristics. Survival curves were estimated using the Kaplan-Meier method and compared using the log rank test. Results. We identified 87 patients with uterine CS and 18 with ovarian CS. There was no difference in age, body mass index, parity, menopausal status, family history of cancer, history of pelvic radiation, diabetes or hypertension between the two groups. 43% of women with uterine CS presented at stage I/II, compared to 28% of women with ovarian tumors (P = 0.0003). 82% of patients with ovarian tumors received adjuvant chemotherapy with or without radiation; 51% of the patients in the uterine CS group received adjuvant radiation therapy. The median length of follow-up was 13 months. There was no difference in the Kaplan-Meier estimates of overall survival between the two disease sites. The median survival for uterine CS patients was 16 months, compared to 11 months in the ovarian CS group; HR = 0.991 (95% CI = 0.534, 1.839). Conclusions. We found no differences in patient demographics between the two groups. Despite differences in stage and initial treatment, there was no difference in survival between women with uterine and ovarian CS.

KW - Carcinosarcoma

KW - Cervix

KW - Ovary

UR - http://www.scopus.com/inward/record.url?scp=32644480086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32644480086&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.09.017

DO - 10.1016/j.ygyno.2005.09.017

M3 - Article

C2 - 16271748

AN - SCOPUS:32644480086

VL - 100

SP - 561

EP - 564

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -